Our results suggest that progression of inflammation, hepatic fibrosis, and hepatic lipid metabolism disorder during NASH may influence the expression and scavenger functions of FcγRIIb in LSECs. The gene discussed is FCGR2B; the disease is Hepatic fibrosis.